Abstract:Although genome-wide association studies (GWAS) have identified loci associated with Type 1 diabetes (T1D), the specific pathways and regulatory networks linking these loci to disease pathology remain largely unknown. We hypothesized that T1D genetic risk factors disrupt tissue-specific biological pathways and gene networks that ultimately lead to beta cell loss. We conducted a multitissue multiomics analysis that integrates human GWAS data for T1D with tissue-specific regulatory data on gene expression and gene network models across relevant tissues to highlight key pathways and key driver genes contributing to T1D pathogenesis. Key driver genes were validated using islet-specific gene expression and protein data from non-obese diabetic (NOD) mice compared to non-T1D mouse models. Drug repositioning predictions were generated using the L1000 and PharmOmics platforms. Our integrative genomics approach identified known immune pathways across multiple tissues, such as adaptive immune responses, cytokine-mediated inflammation, primary immunodeficiency, and interactions between lymphoid and non-lymphoid cells. Tissue-specific signals included genes related to type 2 diabetes in lymphocytes, viral response pathways in macrophages and monocytes, and Notch signaling in adipose and immune cells. In pancreatic islet analysis, we observed significant enrichment for T1D and type 2 diabetes gene sets alongside immune-related pathways, including antigen processing, systemic lupus erythematosus, and interferon signaling. Removing HLA genes from the analysis revealed additional immune pathways, such as RIG-I/MDA5 induction of interferons, along with melanogenesis, steroid hormone synthesis, and iron transport. Network modeling highlighted the autoimmune basis of disease with key drivers such as FYN, TAP1, WAS, and HLA-B/C/G, as well as further immunomodulatory genes such as LCK, LCP2, EMR1, and GC. These key drivers were further supported by gene and protein expression data from NOD mice. We additionally highlight various drug classes that target the T1D genetic networks and may be useful to delay T1D development. Our multitissue multiomics approach provides a detailed landscape of the tissue-specific genetic networks and regulators underlying T1D. This analysis confirms the roles of known immune pathways while uncovering additional regulatory elements and disease-associated networks, thus expanding our understanding of T1D pathogenesis. The identification of potential drug candidates through network analysis offers potential therapeutic strategies for targeting disease pathways and holds promise for delaying or preventing T1D progression.

Multi-tissue Transcriptome-Wide Association Study Reveals Susceptibility Genes and Drug Targets for Insulin Resistance-Relevant Phenotypes

Multi-omics Analysis to Identify Susceptibility Genes for Colorectal Cancer.

Functional Screening of Candidate Causal Genes for Insulin Resistance in Human Preadipocytes and Adipocytes

High-throughput Functional Dissection of Noncoding SNPs with Biased Allelic Enhancer Activity for Insulin Resistance-Relevant Phenotypes

Comprehensive genetic study of the insulin resistance marker TG:HDL-C in the UK Biobank

Genome-wide discovery and integrative genomic characterization of insulin resistance loci using serum triglycerides to HDL-cholesterol ratio as a proxy

The Identification of a Novel Shared Therapeutic Target and Drug Across All Insulin-Sensitive Tissues under Insulin Resistance

Modulation by dietary fat and carbohydrate of IRS1 association with type 2 diabetes traits in two populations of different ancestries.

Based on systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for diabetes

Potential disease biomarkers for diabetic retinopathy identified through Mendelian randomization analysis

Transcriptome-wide Mendelian Randomization During CD4+ T Cell Activation Reveals Immune-Related Drug Targets for Cardiometabolic Diseases

Multitissue Multiomics Integration Reveals Tissue-Specific Pathways, Gene Networks, and Drug Candidates for Type 1 Diabetes

Genome-wide association study and functional characterization identifies candidate genes for insulin-stimulated glucose uptake

Proteomic Analyses in Diverse Populations Improved Risk Prediction and Identified New Drug Targets for Type 2 Diabetes

Network Mendelian randomisation analysis deciphers protein pathways linking type 2 diabetes and gastrointestinal disease

Genome-wide Association Study Identifies Novel Loci Association with Fasting Insulin and Insulin Resistance in African Americans

Mitochondrial dysfunction and onset of type 2 diabetes along with its complications: a multi-omics Mendelian randomization and colocalization study

In-silico identification and functional characterization of common genes associated with type 2 diabetes and hypertension

Interactome-transcriptome Analysis Discovers Signatures Complementary to GWAS Loci of Type 2 Diabetes

System Network Analysis of Genomics and Transcriptomics Data Identified Type 1 Diabetes-Associated Pathway and Genes.